10-Q: Henry Schein Q2 Profit Dips Amid Restructuring, Sales Up

Henry Schein, Inc. reported a 3.3% increase in net sales for Q2 2025, reaching $3.24 billion, but net income attributable to the company declined by 17.3% to $86 million.

Summary

• Net sales for the three months ended June 28, 2025, increased by 3.3% to $3.24 billion, up from $3.14 billion in the prior year period.
• Net sales for the six months ended June 28, 2025, increased by 1.6% to $6.41 billion, up from $6.31 billion in the prior year period.
• Net income attributable to Henry Schein, Inc. for Q2 2025 was $86 million, a decrease of 17.3% from $104 million in Q2 2024.
• Diluted earnings per share (EPS) for Q2 2025 decreased to $0.70 from $0.80 in Q2 2024.
• Gross profit for Q2 2025 was $1.02 billion, a slight decrease from $1.02 billion in Q2 2024, with gross margin declining to 31.4% from 32.5%.
• Operating income for Q2 2025 was $151 million, down from $159 million in Q2 2024.
• Net cash provided by operating activities for the six months ended June 28, 2025, significantly decreased to $157 million from $493 million in the prior year period.
• The company incurred $23 million in restructuring charges in Q2 2025 and $48 million year-to-date 2025 related to the 2024 Plan.
• Received $20 million in insurance proceeds during Q1 2025, representing the remaining recovery for the October 2023 cyber incident.
• Issued 3,285,151 shares of common stock to funds affiliated with KKR for $250 million on May 16, 2025, resulting in KKR owning approximately 12.5% of common stock.
• Executed a $250 million accelerated share repurchase program on May 19, 2025, receiving 3,122,832 shares by June 28, 2025, with final shares received in July 2025.

Sentiment

Score: 5

Explanation: The filing presents a mixed financial picture with revenue growth offset by declines in profitability and operating cash flow for the quarter. Strategic capital actions like the KKR investment and share repurchases are positive, but ongoing restructuring costs and potential regulatory headwinds introduce uncertainty, leading to a neutral-to-slightly negative sentiment.

Positives

• Overall net sales increased by 3.3% for the three months and 1.6% for the six months ended June 28, 2025.
• Global Technology segment sales increased by 7.4% for the three months and 5.1% for the six months, driven by cloud-based software users and revenue cycle management solutions.
• Global Medical sales increased by 6.1% for the three months and 4.4% for the six months, attributed to increased patient traffic and growth in the Home Solutions business.
• Strategic investment by KKR of $250 million and the execution of a $250 million accelerated share repurchase program demonstrate confidence and return capital to shareholders.
• The company completed accounting for the TriMed Inc. acquisition, which is expected to provide synergies and growth potential in the Global Specialty Products segment.
• Received the remaining $20 million in insurance proceeds for the October 2023 cyber incident, indicating a resolution of financial recovery related to the event.
• Operating expenses decreased by 1.8% for the six months ended June 28, 2025, partly due to cost savings from restructuring activities and operating efficiencies.
• The Revolving Credit Agreement and Term Loan were amended to extend maturity dates, improving debt structure and liquidity management.

Negatives

• Net income attributable to Henry Schein, Inc. decreased by 17.3% for the three months ended June 28, 2025, and slightly by 0.5% for the six months.
• Diluted earnings per share declined to $0.70 in Q2 2025 from $0.80 in Q2 2024.
• Gross profit margin decreased to 31.4% in Q2 2025 from 32.5% in Q2 2024, primarily due to lower glove pricing and targeted sales initiatives in Global Distribution and Value-Added Services.
• Operating income decreased by 5.0% for the three months ended June 28, 2025.
• Net cash provided by operating activities significantly decreased to $157 million for the six months ended June 28, 2025, compared to $493 million in the prior year, primarily due to changes in working capital accounts and normalization of cash collections post-cyber incident.
• Ongoing restructuring costs from the 2024 Plan amounted to $23 million in Q2 2025 and $48 million year-to-date, with further charges expected through 2025.
• U.S. dental equipment sales were temporarily impacted by market uncertainty related to tariffs in the second half of Q2 2025.
• Lower sales in the practice transitions business contributed to a decrease in internally generated local currency value-added services sales.

Risks

• The recently signed One Big Beautiful Bill Act (OBBBA) in the U.S. is expected to result in substantial reductions in Medicaid enrollees and federal funding to state Medicaid programs, potentially adversely impacting utilization of services and product coverage.
• The OBBBA also includes significant changes to corporate tax rates, deductions, and international tax provisions, the full impact of which is still being assessed.
• Ongoing geopolitical conflicts (e.g., war in Ukraine, Israel-Gaza war) and public unrest could impact global operations and supply chains.
• Fluctuations in foreign currency exchange rates, particularly the Brazilian Real, British Pound, Euro, Swiss Franc, Canadian Dollar, New Zealand Dollar, and Israel Shekel, can significantly impact comprehensive income.
• The company is a defendant in multiple opioid-related lawsuits, though settlements for immaterial amounts have been reached in some cases, and the company intends to vigorously defend itself against remaining actions.
• Changes in accounts receivable collection patterns could reduce the company's ability to borrow under its U.S. trade accounts receivable securitization facility.
• The company's ability to generate sufficient cash flows from operations is dependent on continued customer demand and access to products from suppliers, which could be affected by economic conditions.

Future Outlook

The company expects to record additional restructuring charges associated with the 2024 Plan through the end of 2025. It is currently assessing the impact of the newly signed One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements, which includes significant changes to corporate tax rates and potential reductions in Medicaid enrollees and funding. The company believes demand for its products and services will grow, influenced by an aging population and increased healthcare awareness, but will continue to be impacted by operating, economic, and industry conditions.

Management Comments

• "Our gross margins may not necessarily be comparable to other distribution companies due to different practices of categorizing costs associated with distribution networks."
• "We believe that we are positioned to capitalize on the industry consolidation trend, as we believe we have the ability to support increased sales through our existing infrastructure."
• "We believe that demand for our products and services will grow while continuing to be impacted by current and future operating, economic and industry conditions."
• "We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs."

Industry Context

The healthcare industry continues to focus on cost containment, benefiting distributors offering broad product arrays at competitive prices. This trend also accelerates the growth of large entities like DSOs, GPOs, and group practices, which favor distributors capable of providing specialized management information support. The aging global population is a key driver of demand for healthcare services and products, with significant projected growth in older age groups. Government regulations, including new tariffs and the recently enacted OBBBA, are creating a volatile environment for global trade and healthcare funding, potentially impacting utilization, payment, and production costs. The industry is also seeing increased enforcement activity in areas like fraud, abuse, and data privacy.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in multiple opioid-related lawsuits (currently less than 100), alleging improper distribution of drugs.
• Reached a settlement agreement in principle with hospital plaintiffs in sixteen cases for an immaterial amount, leading to a stay of trial.
• Agreed to settle fifty-nine cases filed by Virginia municipalities for an immaterial amount, with finalization pending.
• Opioid sales represented less than four-tenths of 1 percent of the company's 2024 net sales.
• Accrued best estimate of potential losses for probable claims, which was not material to financial position, results of operations, or cash flows as of June 28, 2025.

Related Party Transactions

• Joint venture with Internet Brands to create Henry Schein One, LLC, with Internet Brands holding a 33.6% noncontrolling interest.
• Memorandum of Understanding signed on January 29, 2025, to extend Henry Schein's call option to July 1, 2032, and pause Internet Brands' put option to January 29, 2029.
• Annual royalty payments of approximately $31 million to Internet Brands for intellectual property use.
• Net sales of $28 million to equity affiliates and purchases of $5 million from equity affiliates for the six months ended June 28, 2025.
• Aggregate $30 million due from equity affiliates and $7 million due to equity affiliates as of June 28, 2025.
• Operating leases with employees and minority shareholders, with current liabilities of $6 million and non-current liabilities of $22 million as of June 28, 2025, representing 6.9% and 8.7% of total current and non-current operating lease liabilities, respectively.

Stakeholder Impact

• Shareholders: Impacted by declining net income and EPS, but also by the KKR strategic investment and accelerated share repurchase program, which could support share price and return capital.
• Employees: Affected by ongoing restructuring plans (2024 Plan) which include severance and employee-related costs, indicating potential job reductions. Executive employees benefit from changes to the Supplemental Executive Retirement Plan.
• Customers: May experience impacts from lower glove pricing and targeted sales initiatives, as well as potential changes in service utilization due to the OBBBA's impact on Medicaid.
• Creditors: Debt structure changes, including extended maturities for revolving credit and term loans, provide more stability, but increased borrowings could raise leverage concerns.
• Suppliers: No direct impact mentioned, but overall business performance and market conditions could indirectly affect relationships.

Next Steps

• Continue to record restructuring charges associated with the 2024 Plan through the end of 2025.
• Assess the full impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Make quarterly payments of $5 million on the Term Credit Agreement starting June 2026, increasing to $9 million in September 2027.
• Monitor the impact of Pillar Two rules on the effective tax rate and cash tax liabilities.
• Continue to defend against remaining opioid-related lawsuits.
• Potentially purchase additional shares via open market purchases by KKR up to a total equity stake of 14.9%.
• Utilize the remaining $432 million authorized for future common stock share repurchases.

Key Dates

Recommendation

The company exhibits a mixed financial performance with revenue growth but a decline in profitability and operating cash flow for the quarter. While strategic initiatives like the KKR investment and accelerated share repurchases are positive for shareholder value and demonstrate confidence, the ongoing restructuring costs and potential headwinds from new tax legislation (OBBBA) and tariffs introduce uncertainty. The significant drop in operating cash flow is a concern that warrants close monitoring. A 'hold' recommendation is appropriate, acknowledging the company's efforts to streamline operations and enhance shareholder value, while remaining cautious about the near-term profitability and cash flow challenges.

Keywords

Healthcare distribution, Dental supplies, Medical supplies, Practice management software, SEC filing, Quarterly results, Financial performance, Restructuring, Cybersecurity, Acquisitions, Debt financing, Share repurchase, KKR investment, Opioid litigation, Tax reform